Alzheimer's disease

Carly Oboudiyat, Hilary Glazer, Alon Seifan, Christine Greer, Richard S. Isaacson

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Alzheimer's disease (AD) is the most common neurodegenerative cause of dementia and is responsible for significant individual morbidity and mortality, and economic impact on the health care system. Neurodegeneration (including neuronal atrophy and/or loss) are attributed to extraneuronal toxic amyloid oligomers and proteins, intraneuronal neurofibrillary tangles consisting of hyperphosphorylated tau, region-specific diminished cerebral glucose metabolism, synaptic dysfunction, and mitochondrial dysfunction. Several of these pathologic changes may occur decades before symptom onset, leaving ample time for implementing prevention strategies that target the earliest stages of the disease. In recent years, a myriad of modifiable and nonmodifiable risk factors have been elucidated. We describe the latest criteria for the diagnosis of AD, including earliest diagnostic stage of preclinical AD, which has the highest potential for research, including diagnosis and disease modification. We discuss both FDA-approved pharmacologic treatments, as well as nonpharmacologic strategies for AD therapeutics, including prevention via evidence-based, low-risk interventions. Genotype is an important consideration in managing patients on the AD continuum, as presence of the APOE ε4 allele may influence response to treatment. We present the most current evidence relating to pharmacogenomics, nutrigenomics, and distinctive nutritional requirements targeted toward AD.

Original languageEnglish
Pages (from-to)313-329
Number of pages17
JournalSeminars in Neurology
Volume33
Issue number4
DOIs
StatePublished - Nov 22 2013

Fingerprint

Alzheimer Disease
Nutrigenomics
Amyloidogenic Proteins
Nutritional Requirements
Neurofibrillary Tangles
Poisons
Pharmacogenetics
Delayed Diagnosis
Atrophy
Dementia
Therapeutics
Alleles
Genotype
Economics
Morbidity
Delivery of Health Care
Glucose
Mortality
Research

Keywords

  • Alzheimer's diet
  • Alzheimer's disease
  • Alzheimer's prevention
  • APOE ε4
  • beta amyloid
  • brain glucose hypometabolism
  • diet
  • ketogenic diet
  • ketone bodies
  • ketosis
  • major neurocognitive disorder
  • medical foods
  • mild cognitive impairment
  • mild neurocognitive disorder
  • NIA-AA criteria
  • nonpharmacologic therapy
  • nutrigenomics
  • pharmacogenomics
  • preclinical Alzheimer's disease
  • supplements
  • tau

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Oboudiyat, C., Glazer, H., Seifan, A., Greer, C., & Isaacson, R. S. (2013). Alzheimer's disease. Seminars in Neurology, 33(4), 313-329. https://doi.org/10.1055/s-0033-1359319

Alzheimer's disease. / Oboudiyat, Carly; Glazer, Hilary; Seifan, Alon; Greer, Christine; Isaacson, Richard S.

In: Seminars in Neurology, Vol. 33, No. 4, 22.11.2013, p. 313-329.

Research output: Contribution to journalArticle

Oboudiyat, C, Glazer, H, Seifan, A, Greer, C & Isaacson, RS 2013, 'Alzheimer's disease', Seminars in Neurology, vol. 33, no. 4, pp. 313-329. https://doi.org/10.1055/s-0033-1359319
Oboudiyat C, Glazer H, Seifan A, Greer C, Isaacson RS. Alzheimer's disease. Seminars in Neurology. 2013 Nov 22;33(4):313-329. https://doi.org/10.1055/s-0033-1359319
Oboudiyat, Carly ; Glazer, Hilary ; Seifan, Alon ; Greer, Christine ; Isaacson, Richard S. / Alzheimer's disease. In: Seminars in Neurology. 2013 ; Vol. 33, No. 4. pp. 313-329.
@article{90c834d99a47484da93cf7071633790b,
title = "Alzheimer's disease",
abstract = "Alzheimer's disease (AD) is the most common neurodegenerative cause of dementia and is responsible for significant individual morbidity and mortality, and economic impact on the health care system. Neurodegeneration (including neuronal atrophy and/or loss) are attributed to extraneuronal toxic amyloid oligomers and proteins, intraneuronal neurofibrillary tangles consisting of hyperphosphorylated tau, region-specific diminished cerebral glucose metabolism, synaptic dysfunction, and mitochondrial dysfunction. Several of these pathologic changes may occur decades before symptom onset, leaving ample time for implementing prevention strategies that target the earliest stages of the disease. In recent years, a myriad of modifiable and nonmodifiable risk factors have been elucidated. We describe the latest criteria for the diagnosis of AD, including earliest diagnostic stage of preclinical AD, which has the highest potential for research, including diagnosis and disease modification. We discuss both FDA-approved pharmacologic treatments, as well as nonpharmacologic strategies for AD therapeutics, including prevention via evidence-based, low-risk interventions. Genotype is an important consideration in managing patients on the AD continuum, as presence of the APOE ε4 allele may influence response to treatment. We present the most current evidence relating to pharmacogenomics, nutrigenomics, and distinctive nutritional requirements targeted toward AD.",
keywords = "Alzheimer's diet, Alzheimer's disease, Alzheimer's prevention, APOE ε4, beta amyloid, brain glucose hypometabolism, diet, ketogenic diet, ketone bodies, ketosis, major neurocognitive disorder, medical foods, mild cognitive impairment, mild neurocognitive disorder, NIA-AA criteria, nonpharmacologic therapy, nutrigenomics, pharmacogenomics, preclinical Alzheimer's disease, supplements, tau",
author = "Carly Oboudiyat and Hilary Glazer and Alon Seifan and Christine Greer and Isaacson, {Richard S.}",
year = "2013",
month = "11",
day = "22",
doi = "10.1055/s-0033-1359319",
language = "English",
volume = "33",
pages = "313--329",
journal = "Seminars in Neurology",
issn = "0271-8235",
publisher = "Thieme Medical Publishers",
number = "4",

}

TY - JOUR

T1 - Alzheimer's disease

AU - Oboudiyat, Carly

AU - Glazer, Hilary

AU - Seifan, Alon

AU - Greer, Christine

AU - Isaacson, Richard S.

PY - 2013/11/22

Y1 - 2013/11/22

N2 - Alzheimer's disease (AD) is the most common neurodegenerative cause of dementia and is responsible for significant individual morbidity and mortality, and economic impact on the health care system. Neurodegeneration (including neuronal atrophy and/or loss) are attributed to extraneuronal toxic amyloid oligomers and proteins, intraneuronal neurofibrillary tangles consisting of hyperphosphorylated tau, region-specific diminished cerebral glucose metabolism, synaptic dysfunction, and mitochondrial dysfunction. Several of these pathologic changes may occur decades before symptom onset, leaving ample time for implementing prevention strategies that target the earliest stages of the disease. In recent years, a myriad of modifiable and nonmodifiable risk factors have been elucidated. We describe the latest criteria for the diagnosis of AD, including earliest diagnostic stage of preclinical AD, which has the highest potential for research, including diagnosis and disease modification. We discuss both FDA-approved pharmacologic treatments, as well as nonpharmacologic strategies for AD therapeutics, including prevention via evidence-based, low-risk interventions. Genotype is an important consideration in managing patients on the AD continuum, as presence of the APOE ε4 allele may influence response to treatment. We present the most current evidence relating to pharmacogenomics, nutrigenomics, and distinctive nutritional requirements targeted toward AD.

AB - Alzheimer's disease (AD) is the most common neurodegenerative cause of dementia and is responsible for significant individual morbidity and mortality, and economic impact on the health care system. Neurodegeneration (including neuronal atrophy and/or loss) are attributed to extraneuronal toxic amyloid oligomers and proteins, intraneuronal neurofibrillary tangles consisting of hyperphosphorylated tau, region-specific diminished cerebral glucose metabolism, synaptic dysfunction, and mitochondrial dysfunction. Several of these pathologic changes may occur decades before symptom onset, leaving ample time for implementing prevention strategies that target the earliest stages of the disease. In recent years, a myriad of modifiable and nonmodifiable risk factors have been elucidated. We describe the latest criteria for the diagnosis of AD, including earliest diagnostic stage of preclinical AD, which has the highest potential for research, including diagnosis and disease modification. We discuss both FDA-approved pharmacologic treatments, as well as nonpharmacologic strategies for AD therapeutics, including prevention via evidence-based, low-risk interventions. Genotype is an important consideration in managing patients on the AD continuum, as presence of the APOE ε4 allele may influence response to treatment. We present the most current evidence relating to pharmacogenomics, nutrigenomics, and distinctive nutritional requirements targeted toward AD.

KW - Alzheimer's diet

KW - Alzheimer's disease

KW - Alzheimer's prevention

KW - APOE ε4

KW - beta amyloid

KW - brain glucose hypometabolism

KW - diet

KW - ketogenic diet

KW - ketone bodies

KW - ketosis

KW - major neurocognitive disorder

KW - medical foods

KW - mild cognitive impairment

KW - mild neurocognitive disorder

KW - NIA-AA criteria

KW - nonpharmacologic therapy

KW - nutrigenomics

KW - pharmacogenomics

KW - preclinical Alzheimer's disease

KW - supplements

KW - tau

UR - http://www.scopus.com/inward/record.url?scp=84887829898&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887829898&partnerID=8YFLogxK

U2 - 10.1055/s-0033-1359319

DO - 10.1055/s-0033-1359319

M3 - Article

VL - 33

SP - 313

EP - 329

JO - Seminars in Neurology

JF - Seminars in Neurology

SN - 0271-8235

IS - 4

ER -